The "Company" refers to DexTech Medical AB (org.nr 556664-6203).

Summary of the third quarter (2026-01-01 – 2026-03-31)

• Net sales amounted to SEK 0.0 million (0.0)
• Operating profit amounted to SEK -1.7 million (-1.3)
• Earnings per share* SEK -0.09 (-0.07)

Summary of the nine-month period (2025-07-01 – 2026-03-31)

• Net sales amounted to SEK 0.0 million (0.0)
• Operating profit amounted to SEK -4.8 million (-3.7)
• Earnings per share* SEK -0.25 (-0.18)
• Cash and cash equivalents at the end of the period amounted to SEK 10.1 M (14.7)
• More than 80 percent of patients have transitioned from progressive to stable disease after completing treatment.
• The study shows a very good safety profile, with no serious Osteodex-related side effects.

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year for income statement and cash flow items and the end of the previous financial year for balance sheet items.

Comments from the CEO 

The Company's Phase I/IIa study for OsteoDex (ODX) treatment of patients with relapsed/treatment-resistant multiple myeloma, conducted at Uddevalla Hospital and Karolinska University Hospital Huddinge, is being completed and all patients have completed treatment. Patients with stable disease are followed monthly until new progression.

The results show a very good safety profile, with no serious ODX-related side effects, and that a majority of patients show treatment effect with stable disease after completion of treatment. Follow-up data also indicate that in some cases the effect persists for several months after the end of treatment without other cancer therapy.

The results are more positive than could be expected and supplemented with other analysis results, the overall result can be further strengthened. The formal study report (CSR) is expected to be completed in the third quarter of 2026, slightly later than previously announced.

As previously announced, updated cost forecasts and current liquidity show that working capital is sufficient to finance the current operations until the end of 2028.

Anders R Holmberg

Contact persons

Anders Holmberg, CEO, +46 73 324 27 82

Gösta Lundgren, CFO, +46 70 710 47 88

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on May 5, 2026.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The lead candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail existing drugs. DexTech's goal is to out-license each drug candidate no later than after completion of the phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.